Disseminated intravascular coagulation (DIC) is a very rare complication of pulmonary tuberculosis. We herein describe a case of cavitary tuberculosis complicated with DIC. Rifampin was considered to deteriorate the clinical course of DICin this case. (Internal Medicine 36: 218-220, 1997) 
Introduction
Disseminated intravascular coagulation (DIC) is considered to be an emergency life-threatening problem in the internal medicine field. DIC is typically associated with underlying disease such as an infection or a malignancy. Miliary tuberculosis is well known to cause DIC, while pulmonary tuberculosis seldom causes DIC. Here, we report a case ofDIC complicated with pulmonary tuberculosis. This case showed an interesting clinical course ofDICassociated with anti-tuberculous therapy.
Case Report
A 43-year-old man was referred to our hospital for antituberculous therapy. His chest roentgenography on admission ( Fig. 1 ) showed left apical cavitary change, infiltrates predominantly in the left lung field, and nodules on the right apex. There were manyacid-fast bacilli in his sputum. Onadmission both liver dysfunction (aspartate aminotransferase: 1 03 U//, alanine aminotransferase: 53 U//, and hepatitis C virus antibody: positive) and thrombocytopenia (platelet: 32,000/mm3) were observed. White blood cell count was slightly elevated (10,900/ mm3). Other laboratory data were as follows: red blood cell count429 x 104/mm\ hemoglobin 12. 1 g/dl, hematocrit 36.3%, and C-reactive protein 1 1.9 mg/dl. The physical examination showed no tendency of bleeding. The findings of chest computed tomography (Fig. 2) , ocular fundus, and bone marrow tapping revealed no evidence of miliary tuberculosis. We started anti-tuberculous therapy with isoniazid (400 mg/ day), rifampin (450 mg/day), and streptomycin ( 1 g/day, twice a week). Whenwe noticed a bleeding tendency, his thrombocytopenia had already progressed ( 1 3,000/mm3) at one week after start of the therapy. Laboratory data supported the diagnosis of DIC (prothrombin time 12.9 seconds, partial thromboplastin time 44.9 seconds, fibrin degradation products above 40 jug/ml, fibrinogen 473 mg/dl, D-dimer 1 ,235 Jig/ml, and platelet associated IgG negative). Wecould differentiate his thrombocytopenia from liver cirrhosis by abdominal ultrasonography. Heparin was started as anti-coagulant therapy (10,000 U/ DIC and Pulmonary Tuberculosis day). Since the possibility ofrifampin-induced thrombocytopenia was considered, wediscontinued rifampin as well as the intramuscular injection of streptomycin. Then we started ethambutol (1 g/day) and pyrazinamide (1.5 g/day) in place of these drugs. A few days after the start of this therapy, his platelet counts slightly increased (platelet; 26,000/mm3). Since therapy for the underlying disease is essential for DIC, we started rifampin again. Although the anti-coagulant therapy was continued, his platelet counts decreased again (platelet; 15,000/ mm3).The platelet counts increased again after we stopped rifampin (platelet; 28,000/mm3). We could observe his clinical course without administrating heparin. Thereafter, we re-started rifampin at a dose of 300 mg/day. There wasno apparent effect of rifampin on the platelet counts at this dose without the anti-coagulant therapy (platelet; 29,000/ mm3). After we increased the dose of rifampin, however, DIC progressed (platelet 18,000/mm3, prothrombin time 12.7 seconds, partial thromboplastin time 62.4 seconds, fibrin degradation products between 10 and 40 Jig/ml, fibrinogen 5 14 mg/dl). Thus we returned rifampin to 300 mg/day and re-started the anti-coagulant therapy (heparin; 1 0,000 U/day). Eventually his platelet counts increased after the improvement of tuberculosis was achieved (platelet; 101,000/mm3). The clinical course is summarized in Fig. 3 . In addition, the hematologic data during The platelet counts tended to decrease after the start of rifampin. The hematologic data from Dec. 15 to Jan. 29 are shown in Table1. the early phase of DIC is summarized in Table 1 .
Discussion
The incidence of tuberculosis has recently been increasing throughout the world ( 1). In Japan more than 50,000 people are registered as newtuberculosis patients every year. DICis a rare complication of tuberculosis, however, it is an emergency lifethreatening problem. Most cases of DIC associated with tuberculosis are miliary tuberculosis (2). Only a few cases of DIC complicated with pulmonary tuberculosis have been reported (3) (4) (5) (6) Treatment of the underlying disease is the first line approach to DIC and rifampin is one of the most important drugs in the treatment of tuberculosis. Weconclude that some special attention is needed for anti-tuberculous therapy in the tuberculosis patients with DIC.
